In a report released yesterday, Tom Jones from Berenberg Bank maintained a Buy rating on Grifols (0RDU – Research Report), with a price target ...

Berenberg analyst Tom Jones lowered the firm’s price target on Grifols (GRFS) to EUR 15.25 from EUR 15.40 and keeps a Buy rating on the ...

‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms appear, leading to new diagnostic tools and ...

The selective Spanish stock market, the IBEX 35, continues to extend gains and is already up 0.80% at noon, standing above 12 ...

(Bloomberg) -- Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator to bolster their cases as they prepare to face off in ...

PR Newswire • 9 months ago Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. The addition of the Clayton site in ...

Private equity firm Brookfield has said it is withdrawing from negotiations to take over Grifols, sparking a slump in the Spanish pharma group's share price. The Canadian investment group said it ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.

Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...